These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23496317)

  • 1. Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation.
    Indriolo A; Fagiuoli S; Pasulo L; Fiorino G; Danese S; Ravelli P
    Aliment Pharmacol Ther; 2013 Apr; 37(8):840-2. PubMed ID: 23496317
    [No Abstract]   [Full Text] [Related]  

  • 2. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
    Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
    Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease.
    Kolho KL; Ruuska T; Savilahti E
    Acta Paediatr; 2007 Jan; 96(1):128-30. PubMed ID: 17187619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New inflammatory bowel disease drugs targeting the inflammatory cascade].
    Desreumaux P
    Gastroenterol Clin Biol; 2001 Apr; 25(4 Suppl):B72-8. PubMed ID: 11449147
    [No Abstract]   [Full Text] [Related]  

  • 5. [Efficacy of infliximab in treatment on inflammatory bowel disease and factors affecting the therapeutic effect].
    Zhou Y; Chen Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Dec; 33(12):1833-8. PubMed ID: 24369257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
    Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
    Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing the glucocorticoid dependent inflammatory bowel disease patient.
    Bonner GF
    Semin Gastrointest Dis; 2001 Oct; 12(4):237-44. PubMed ID: 11726077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of inflammatory bowel disease care.
    Sandborn WJ
    Rev Gastroenterol Disord; 2009; 9(3):E69-77. PubMed ID: 19898267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFalpha reduce colitis-associated colorectal carcinogenesis?
    Biancone L; Petruzziello C; Calabrese E; Zorzi F; Naccarato P; Onali S; Pallone F
    Gut; 2009 Dec; 58(12):1703. PubMed ID: 19923350
    [No Abstract]   [Full Text] [Related]  

  • 11. Infliximab: getting the most for your money.
    Irving PM; Gibson PR
    J Gastroenterol Hepatol; 2007 Oct; 22(10):1559-61. PubMed ID: 17845681
    [No Abstract]   [Full Text] [Related]  

  • 12. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.
    Pearce CB; Lawrance IC
    J Gastroenterol Hepatol; 2007 Oct; 22(10):1671-7. PubMed ID: 17845695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?].
    Tanczos BT; Baumgart DC
    Z Gastroenterol; 2006 Jul; 44(7):609-10. PubMed ID: 16823703
    [No Abstract]   [Full Text] [Related]  

  • 14. [Optimizing effect of infliximab upon inflammatory bowel disease].
    Li SR; Sheng JQ; Li SJ; Zhao XJ
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(36):2568-70. PubMed ID: 20137621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
    Reddy JG; Loftus EV
    Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Application of TNF-alpha blocker concentration assays in the treatment of inflammatory bowel diseases].
    Sipponen T; Kolho KL
    Duodecim; 2013; 129(5):499-505. PubMed ID: 23520893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Perspectives in inflammatory bowel diseases treatment].
    Jalocha L; Wojtuń S; Dyrla P; Błaszak A; Wojtkowiak M; Zyśko B; Stelmaszuk T; Gil J
    Pol Merkur Lekarski; 2009 May; 26(155):556-8. PubMed ID: 19606725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease.
    Zhou L; Chen H; Wen Q; Zhang Y
    Eur J Gastroenterol Hepatol; 2012 Jun; 24(6):695-701. PubMed ID: 22387885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates?
    Cannom RR; Kaiser AM; Ault GT; Beart RW; Etzioni DA
    Am Surg; 2009 Oct; 75(10):976-80. PubMed ID: 19886148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic inflammatory bowel disease - new therapies: tumor necrosis factor-antibodies and cytokines].
    Stange EF
    Z Gastroenterol; 2002 Apr; 40 Suppl 1():S90-S1. PubMed ID: 11930299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.